Evidence map›Paper›PMID 31196490›Full record

ArticleSurgical oncology2019

Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years.

Koji Matsuo, Malcolm S Ross, Mayu Yunokawa, Marian S Johnson, Hiroko Machida, Kohei Omatsu, Merieme M Klobocista, Dwight D Im, Shinya Satoh, Tsukasa Baba and 21 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 20 institutions in 2 countries.

Koji MatsuoDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, CA, USA. Electronic address: koji.matsuo@med.usc.edu.
Malcolm S RossDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Magee-Womens Hospital, University of Pittsburgh, PA, USA.
Mayu YunokawaDepartment of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Marian S JohnsonDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky, KY, USA.
Hiroko MachidaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, CA, USA.
Kohei OmatsuDepartment of Gynecology, Cancer Institute Hospital, Tokyo, Japan.
Merieme M KlobocistaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Montefiore Medical Center, NY, USA.
Dwight D ImThe Gynecologic Oncology Center, Mercy Medical Center, Baltimore, MD, USA.
Shinya SatohDepartment of Obstetrics and Gynecology, Tottori University, Tottori, Japan.
Tsukasa BabaDepartment of Obstetrics and Gynecology, Kyoto University, Kyoto, Japan.
Yuji IkedaDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
Stephen H BushDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Moffitt Cancer Center, University of South Florida, FL, USA.
Kosei HasegawaDepartment of Obstetrics and Gynecology, Saitama Medical University International Medical Center, Saitama, Japan.
Erin A BlakeDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado, CO, USA.
Munetaka TakekumaDepartment of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
Masako ShidaDepartment of Obstetrics and Gynecology, Tokai University, Kanagawa, Japan.
Masato NishimuraDepartment of Obstetrics and Gynecology, Tokushima University, Tokushima, Japan.
Sosuke AdachiDepartment of Obstetrics and Gynecology, Niigata University, Niigata, Japan.
Tanja PejovicDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Oregon Health & Science University, OR, USA.
Satoshi TakeuchiDepartment of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan.
Takuhei YokoyamaDepartment of Obstetrics and Gynecology, Osaka Rosai Hospital, Osaka, Japan.
Yutaka UedaDepartment of Obstetrics and Gynecology, Osaka University, Osaka, Japan.
Keita IwasakiDepartment of Obstetrics and Gynecology, Aichi Medical University, Aichi, Japan.
Takahito M MiyakeDepartment of Obstetrics and Gynecology, Kawasaki Medical School, Okayama, Japan.
Shiori YanaiDepartment of Obstetrics and Gynecology, Kurashiki Medical Center, Okayama, Japan.
Tadayoshi NaganoDepartment of Obstetrics and Gynecology, Kitano Hospital, Osaka, Japan.
Tadao TakanoDepartment of Obstetrics and Gynecology, Tohoku University, Miyagi, Japan.
Mian Mk ShahzadDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Moffitt Cancer Center, University of South Florida, FL, USA.
Frederick R UelandDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky, KY, USA.
Joseph L KelleyDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Magee-Womens Hospital, University of Pittsburgh, PA, USA.
Lynda D RomanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, CA, USA.
University of Southern California · USUniversity of Kentucky · USUniversity of Pittsburgh · USUniversity of South Florida · USAichi Medical University · JPAlbert Einstein College of Medicine · USIwate Medical University · JPKawasaki Medical School · JPKitano Hospital · JPKurashiki Medical Center · JPKyoto University · JPMercy Medical Center · USNiigata University · JPOregon Health & Science University · USOsaka Rosai Hospital · JPSaitama Medical University · JPShizuoka Cancer Center · JPThe Cancer Institute Hospital · JPThe University of Osaka · JPThe University of Tokyo · JP

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI VERONICA WENDY SETIAWAN · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

objectiveTo examine clinico-pathological characteristics and outcomes of uterine carcinosarcoma (UCS) in women aged ≥80 years.

methodsThis is a secondary analysis of a previous multicenter retrospective study examining 906 women with stage I-IV UCS who underwent primary hysterectomy. Patient demographics, treatment types, tumor characteristics, and survival were examined across aged ≥80 (n = 82 [9.1%]), aged 60-79, (n = 526 [58.1%]), and aged <60 (n = 298 [32.9%]).

resultsWomen in the aged ≥80 group were more likely to be Caucasian, undergo simple hysterectomy without lymphadenectomy, and receive no postoperative therapy (all, P < 0.05). Tumors in the aged ≥80 group were more likely to have high-grade carcinoma, heterologous sarcoma, and sarcoma dominance but less likely to have lympho-vascular space invasion (all, P < 0.05). Lymphadenectomy did not improve survival in the aged ≥80 group (P > 0.05), whereas lymphadenectomy was protective for survival in the younger groups (both, P < 0.05). Postoperative chemotherapy was associated with improved progression-free survival (PFS) in the aged ≥80 group (hazard ratio [HR] 0.44, 95% confidence interval [CI] 0.22-0.89, P = 0.021). With chemotherapy treatment, women in the aged ≥80 group had PFS similar to those in the aged 60-79 group (HR 0.97, 95%CI 0.51-1.83, P = 0.92). In contrast, without chemotherapy treatment, women in the aged ≥80 group had significantly decreased PFS compared to the aged 60-79 group (HR 1.62, 95%CI 1.09-2.40, P = 0.016). Similar associations were observed for postoperative radiotherapy.

conclusionNearly 10% of women with UCS are aged ≥80 that are characterized by aggressive tumor factors. Postoperative therapy but not extensive surgery may improve survival in this age group.

Indexed as

AgedAged, 80 and overCarcinosarcomaChemotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansHysterectomyLymph Node ExcisionMiddle AgedNeoplasm InvasivenessPrognosisRadiotherapy, AdjuvantRetrospective StudiesSurvival RateAdjuvant therapyElderlyOldest oldSurgerySurvivalUterine carcinosarcoma

Identifiers

PMID31196490
PMCPMC7523232
OpenAlexW2911489574

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.